HC Wainwright Has Bullish Outlook for FENC FY2026 Earnings

Fennec Pharmaceuticals Inc (NASDAQ:FENC - Free Report) - Equities researchers at HC Wainwright increased their FY2026 earnings per share estimates for shares of Fennec Pharmaceuticals in a research report issued on Tuesday, May 20th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings per share of $0.66 for the year, up from their prior estimate of $0.63. HC Wainwright currently has a "Buy" rating and a $13.00 price objective on the stock. The consensus estimate for Fennec Pharmaceuticals' current full-year earnings is ($0.11) per share.

Fennec Pharmaceuticals (NASDAQ:FENC - Get Free Report) last issued its earnings results on Tuesday, May 13th. The company reported ($0.04) EPS for the quarter, beating analysts' consensus estimates of ($0.12) by $0.08. Fennec Pharmaceuticals had a negative return on equity of 53.38% and a negative net margin of 2.30%. The business had revenue of $8.51 million during the quarter, compared to analyst estimates of $8.18 million. During the same period in the prior year, the company posted $0.41 earnings per share.

Several other analysts have also weighed in on the stock. Craig Hallum lifted their target price on shares of Fennec Pharmaceuticals from $12.00 to $13.00 and gave the company a "buy" rating in a research report on Wednesday, May 14th. Wedbush restated an "outperform" rating and set a $13.00 price target on shares of Fennec Pharmaceuticals in a research note on Monday, March 10th.

Fennec Pharmaceuticals Price Performance

Shares of Fennec Pharmaceuticals stock opened at $8.17 on Wednesday. Fennec Pharmaceuticals has a 52-week low of $3.96 and a 52-week high of $8.26. The firm has a market capitalization of $225.65 million, a PE ratio of -81.69 and a beta of 0.32. The company's fifty day moving average price is $5.97 and its two-hundred day moving average price is $5.99.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Jane Street Group LLC acquired a new stake in shares of Fennec Pharmaceuticals during the 1st quarter worth approximately $90,000. AQR Capital Management LLC acquired a new stake in Fennec Pharmaceuticals during the 1st quarter worth $66,000. Nuveen LLC acquired a new stake in Fennec Pharmaceuticals during the 1st quarter worth $158,000. AIGH Capital Management LLC bought a new stake in shares of Fennec Pharmaceuticals during the 1st quarter valued at $2,199,000. Finally, Pinnacle Wealth Planning Services Inc. bought a new stake in shares of Fennec Pharmaceuticals during the 4th quarter valued at $97,000. 55.51% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, CEO Jeffrey S. Hackman acquired 13,965 shares of the stock in a transaction that occurred on Monday, May 19th. The stock was purchased at an average cost of $6.99 per share, for a total transaction of $97,615.35. Following the completion of the transaction, the chief executive officer now directly owns 15,000 shares in the company, valued at $104,850. This trade represents a 1,349.28% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Rosty Raykov sold 10,000 shares of Fennec Pharmaceuticals stock in a transaction dated Friday, April 4th. The stock was sold at an average price of $5.25, for a total value of $52,500.00. Following the completion of the sale, the director now owns 61,156 shares of the company's stock, valued at approximately $321,069. The trade was a 14.05% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 30,000 shares of company stock valued at $183,500 over the last three months. 11.76% of the stock is owned by insiders.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.